Orders by weight:
This targeted mutation strain carries a disruption of the Abcc2 gene that encodes multidrug resistance protein 2
Useful for the examination of compound uptake and elimination mechanisms
Useful for studies on drug resistance in tumors
Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
Genetic Background: FVB Background
Origin: The Mrp2 mouse was developed in the laboratory of Alfred Schinkel of the Netherlands Cancer Institute. The model was created through targeting of the Abcc2 gene in 129/Ola-derived E14 ES cells and injecting the targeted cells into C57BL/6 blastocysts. Resultant chimeras were backcrossed to FVB/N for seven generations (N7). Taconic received stock in 2006, and the line was embryo transfer derived. The colony is maintained by mating homozygotes.
Genetics: Wild type for Nnt mutation; carries Pde6brd1 mutation
- Vlaming MLH, Mohrmann K, Wagenaar E, de Waart DR, Oude Elferink RPJ, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JHM, Schinkel AH. (2006) Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318(1):319-327
- van Waterschoot RAB, ter Heine R, Waagenar E, van der Kruijssen CMM, Rooswinkel RW, Huitema ADR, Beijnen JH, Schinkel AH (2010). Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 160(5):1224-1233.